NSG BioLabs and Amgen celebrated the third annual ‘Amgen Golden Ticket competition’ in Singapore, highlighting breakthroughs in biotech innovation.
The initiative, extending for another three years, aims to bolster Singapore’s biotech ecosystem by supporting high-growth startups. PairX Bio won the 2024 Golden Ticket, securing a year-long residency at NSG BioLabs’ state-of-the-art laboratory.
Amgen reaffirmed its commitment to fostering biotech advancements globally and in Singapore, emphasizing mentorship and innovation support for emerging companies like PairX Bio in transforming cancer treatment.
“NSG BioLabs empowers biotech startups by providing top-tier BSL-2 laboratory spaces, offering scientists a conducive environment to conduct their research, and bring their ideas to fruition.
NSG BioLabs and Amgen CEOs
By fostering connections between leading pharmaceutical companies and pioneering startups, we cultivate collaboration that drives healthcare advancements. We deeply appreciate our strong partnership with the Amgen team and look forward to future collaborations with other industry leaders,” says Daphne Teo, CEO and Founder, NSG BioLabs.
“Golden Ticket initiatives sponsored by Amgen around the world have been pivotal in fostering innovation and supporting promising companies such as PairX Bio. We remain committed to nurturing the next generation of biotech leaders with our extended commitment through 2027,” states Dr. Alan Russell, Vice President, Biologics Therapeutic Discovery, Amgen.